
CLK inhibitor T3
CAS No. 2109805-56-1
CLK inhibitor T3( T3 )
Catalog No. M13352 CAS No. 2109805-56-1
CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110?nM for CLK1,2 and 3, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 68 | Get Quote |
![]() ![]() |
5MG | 113 | Get Quote |
![]() ![]() |
10MG | 196 | Get Quote |
![]() ![]() |
25MG | 417 | Get Quote |
![]() ![]() |
50MG | 614 | Get Quote |
![]() ![]() |
100MG | 872 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCLK inhibitor T3
-
NoteResearch use only, not for human use.
-
Brief DescriptionCLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110?nM for CLK1,2 and 3, respectively.
-
DescriptionCLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110?nM for CLK1,2 and 3, respectively; displays 200-300-fold selectivity over other dual specificity kinases such as DYRK1A and DYRK1B; induces dose-dependent reduction in exon recognition and exhibits an overlapping, but greater effect on transcriptome splicing compared to KH-CB19.
-
In VitroCLK-IN-T3 inhibits DYRK1A (IC50=260 nM) and DYRK1B (IC50=230 nM). CLK-IN-T3 (0.1-10.0 μM; 24 hours) results in mild cell cycle arrest at the G2/M boundary with long-duration (24 h). CLK-IN-T3 (0.5-1.0 μM; 6 hours) decreases phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. Cell Cycle Analysis Cell Line:HCT-116 cells.Concentration:0.1, 0.5, 1.0, 5.0, 10.0 μM Incubation Time:24 hours Result:Resulted in mild cell cycle arrest at the G2/M boundary with long-duration (24 h).Western Blot Analysis Cell Line:HCT-116 cells Concentration:0.5, 1.0 μM Incubation Time:6 hours Result:Decreased phosphorylation of CLK-targeted SR proteins and CLK proteins increased slightly.
-
In Vivo——
-
SynonymsT3
-
PathwayCell Cycle/DNA Damage
-
TargetCLK
-
RecptorCLK
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number2109805-56-1
-
Formula Weight482.588
-
Molecular FormulaC28H30N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4.83 mg/mL (10.01 mM)
-
SMILESO=C(NC1=CN2C=C(C3=CC=NC=C3)C=CC2=N1)C4=CC=C(C(C)(C)C(N5CCN(C)CC5)=O)C=C4
-
Chemical Name4-(2-methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-N-(6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Funnell T, et al. Nat Commun. 2017 Feb 23;8(1):7.
molnova catalog



related products
-
SRI-29329
A potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively; shows no significant activity for CLK3, CDK1, CDK4 and CDK6 (IC50>1,000 nM).
-
CLK2 inhibitor Indaz...
CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM.
-
ML167
A potent, selective CDC-like kinase 4 (CLK4) inhibitor with IC50 of 136 nM, >10-fold selectivity over Clk1, Clk2, Clk3, Dyrk1A/1B.